Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Vaccine in Recurrent Malignant Glioma
NCT04943718Phase 1Unknown
- Sponsor
- Xuanwu Hospital
- Start
- Jul 2021
- Primary completion
- Jun 2023
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of personalized neoantigen peptide vaccine in malignant glioma, sponsored by Xuanwu Hospital. Primary endpoint: Incidences of adverse events and severe adverse events at 28 weeks. Status: unknown.
02
Drugs
personalized neoantigen peptide vaccine
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT04943718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04943718.